Trials / Completed
CompletedNCT03679767
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
Conditions
- Metastatic Non-small Cell Lung Cancer
- Locally Advanced Urothelial Cancer
- Metastatic Urothelial Cancer
- Unresectable Melanoma
- Metastatic Melanoma
- Locally Advanced Renal Cell Carcinoma
- Metastatic Clear-Cell Renal Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retifanlimab | Retifanlimab administered intravenously at 500 mg every 4 weeks |
Timeline
- Start date
- 2019-01-09
- Primary completion
- 2021-04-15
- Completion
- 2022-06-28
- First posted
- 2018-09-20
- Last updated
- 2023-07-21
- Results posted
- 2022-05-10
Locations
52 sites across 8 countries: United States, Austria, France, Hungary, Italy, Poland, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03679767. Inclusion in this directory is not an endorsement.